Purchase this article with an account.
J. P. Ramirez, R. Velasco, O. Baca, A. Babayan; Autologous Serum in the Treatment of Vernal Keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4743.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the clinical response with autologous serum treatment in patients with vernal keratoconjunctivitis.
This is a longitudinal, prospective and experimental study of cases with vernal keratoconjunctivitis refractive to conventional treatment. Patients were treated with topical autologous serum at 20% every 4 hours. Clinical symptoms and signs were reported before treatment and every week with autologous serum drops. We designed a questionnaire and photographic guide to evaluate treatment response in each patient objectively. Follow up study was one month.
We included 20 eyes of 10 patients with vernal keratoconjunctivits, with a mean average of 9.4 years old 8 were male and 2 were female. The response to treatment with autologous serum was a decrease of 78.13% of the symptoms and 66.27% percent of signs at one month follow up. No adverse effects were presented.
Autologous serum can be an alternative treatment in vernal keratoconjunctivitis with important decrease of signs and symptoms without adverse effects of conventional therapies.
This PDF is available to Subscribers Only